BACKGROUND: Time to treatment onset (TTTO) is critical in breast cancer patients receiving neoadjuvant chemotherapy (NACT). We therefore investigated possible delaying factors of therapy onset. METHODS: All patients were included who qualified for NACT in our hospital from 2015 to 2017. The time interval between core biopsy of tumor and date of therapy onset was defined as primary endpoint. Among other things, age, out- and in-patient presentation, and study or standard treatment were investigated as potentially delaying factors. RESULTS: We analyzed 139 patients scheduled for NACT; 90 (64.7%) received standard NACT, and 49 (35.3%) were recruited for trials. The average age was 53 years (±13.2 years). A time interval of 30.7 days (±11.8 days) was seen between diagnosis and therapy onset. Patients had a mean of 5 (±1.9) pretherapeutic presentations, 4 (±1.8) on outpatient and 1 (±0.5) on inpatient basis, being of significant influence on TTTO. CONCLUSION: Any outpatient presentation extended the time interval by 2 days, inpatient presentation by 4 days. These presentations should be merged in order to minimize TTTO. Neither the site of pathology examinations, additional consultations (genetics, reproductive medicine), nor study participation delayed therapy onset.
BACKGROUND: Time to treatment onset (TTTO) is critical in breast cancer patients receiving neoadjuvant chemotherapy (NACT). We therefore investigated possible delaying factors of therapy onset. METHODS: All patients were included who qualified for NACT in our hospital from 2015 to 2017. The time interval between core biopsy of tumor and date of therapy onset was defined as primary endpoint. Among other things, age, out- and in-patient presentation, and study or standard treatment were investigated as potentially delaying factors. RESULTS: We analyzed 139 patients scheduled for NACT; 90 (64.7%) received standard NACT, and 49 (35.3%) were recruited for trials. The average age was 53 years (±13.2 years). A time interval of 30.7 days (±11.8 days) was seen between diagnosis and therapy onset. Patients had a mean of 5 (±1.9) pretherapeutic presentations, 4 (±1.8) on outpatient and 1 (±0.5) on inpatient basis, being of significant influence on TTTO. CONCLUSION: Any outpatient presentation extended the time interval by 2 days, inpatient presentation by 4 days. These presentations should be merged in order to minimize TTTO. Neither the site of pathology examinations, additional consultations (genetics, reproductive medicine), nor study participation delayed therapy onset.
Authors: A Jo Chien; Julia Chambers; Fiona Mcauley; Tessa Kaplan; Joseph Letourneau; Jimmy Hwang; Mi-Ok Kim; Michelle E Melisko; Hope S Rugo; Laura J Esserman; Mitchell P Rosen Journal: Breast Cancer Res Treat Date: 2017-05-13 Impact factor: 4.872
Authors: Victoria C Hamelinck; Esther Bastiaannet; Arwen H Pieterse; Cornelis J H van de Velde; Gerrit-Jan Liefers; Anne M Stiggelbout Journal: Clin Breast Cancer Date: 2017-11-28 Impact factor: 3.225
Authors: Kemal Beksac; Gokcen Orgul; Ozgur Ozyuncu; Murat Yurdakok; Kadri Altundag; Mehmet S Beksac Journal: Oncol Res Treat Date: 2017-07-13 Impact factor: 2.825
Authors: Manfred Kaufmann; Gunter von Minckwitz; Elefhterios P Mamounas; David Cameron; Lisa A Carey; Massimo Cristofanilli; Carsten Denkert; Wolfgang Eiermann; Michael Gnant; Jay R Harris; Thomas Karn; Cornelia Liedtke; Davide Mauri; Roman Rouzier; Eugen Ruckhaeberle; Vladimir Semiglazov; W Fraser Symmans; Andrew Tutt; Lajos Pusztai Journal: Ann Surg Oncol Date: 2011-12-23 Impact factor: 5.344
Authors: Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor Journal: J Clin Oncol Date: 2014-01-27 Impact factor: 44.544
Authors: Francesco Sardanelli; Hildegunn S Aase; Marina Álvarez; Edward Azavedo; Henk J Baarslag; Corinne Balleyguier; Pascal A Baltzer; Vanesa Beslagic; Ulrich Bick; Dragana Bogdanovic-Stojanovic; Ruta Briediene; Boris Brkljacic; Julia Camps Herrero; Catherine Colin; Eleanor Cornford; Jan Danes; Gérard de Geer; Gul Esen; Andrew Evans; Michael H Fuchsjaeger; Fiona J Gilbert; Oswald Graf; Gormlaith Hargaden; Thomas H Helbich; Sylvia H Heywang-Köbrunner; Valentin Ivanov; Ásbjörn Jónsson; Christiane K Kuhl; Eugenia C Lisencu; Elzbieta Luczynska; Ritse M Mann; Jose C Marques; Laura Martincich; Margarete Mortier; Markus Müller-Schimpfle; Katalin Ormandi; Pietro Panizza; Federica Pediconi; Ruud M Pijnappel; Katja Pinker; Tarja Rissanen; Natalia Rotaru; Gianni Saguatti; Tamar Sella; Jana Slobodníková; Maret Talk; Patrice Taourel; Rubina M Trimboli; Ilse Vejborg; Athina Vourtsis; Gabor Forrai Journal: Eur Radiol Date: 2016-11-02 Impact factor: 5.315
Authors: Gabriel von Waldenfels; Sibylle Loibl; Jenny Furlanetto; Anna Machleidt; Bianca Lederer; Carsten Denkert; Claus Hanusch; Sherko Kümmel; Gunter von Minckwitz; Andreas Schneeweiss; Michael Untch; Kerstin Rhiem; Peter A Fasching; Jens-Uwe Blohmer Journal: Oncotarget Date: 2018-02-26